CLOs on the Move

Locus Pharmaceuticals

www.locuspharma.com

 
Locus Pharmaceuticals, Inc. is a world leader in fragment-based, computational drug design. We have combined highly integrated chemistry, crystallography and biology capabilities to create a unique drug design and development platform for oral drug
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Pique Therapeutics

Pique Therapeutics is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Apexigen, Inc

Apexigen, Inc. is a privately held biopharmaceutical company discovering and developing innovative antibody therapeutics for the treatment of life-threatening and difficult-to-treat diseases. Using its proprietary antibody technology platform, Apexigen has discovered a pipeline of product candidates, which are currently at varying stages of development. The lead product candidate, APX005M, is a novel immuno-oncology antibody that stimulates and enhances an immune response against cancer. Apexigen is developing other product candidates in partnership with four leading biopharmaceutical companies in China. In addition, Apexigen has formed strategic partnerships with multi-national pharmaceutical companies, including Janssen Biotech, Alcon Laboratories and Toray Industries to discover first-in-class antibody lead candidates for the partners' programs.

America's Assisted Living Pharmacy

America's Assisted Living Pharmacy, Inc. is a Paducah, KY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

GuideStar Clinical

GuideStar works with hospitals, health systems and physician practices around the country to build, manage and support clinical research programs. From helping incorporate a clinical trial strategy to providing management guidance and support, our service delivery is based on operational and financial best practices to ensure optimal results for research programs.

Berg Pharma

Berg Pharma focuses research on understanding how alterations in metabolism relate to disease onset. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the Berg Interrogative Biology™ discovery platform that translates biological output into therapeutic candidates, Berg Pharma is well positioned for rapid commercialization of its intellectual capital.